2A Biosciences
Preclinical2 active candidates
2 shared indicationsPreclinical peer2 overlapping stagessame regulator: US FDA
Back to StakeholdersProgramme tracker View landscape
Lead program: Preclinical
Psy Therapeutics
CategoriesEarly-Stage Translational Research (Pre-Clinical)Research, Drug Development & Manufacturing
Data updated
5 Drug Candidates
Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
Psy Therapeutics is a Cambridge, MA-based drug discovery company developing novel small-molecule NCEs for neuropsychiatric and neurological disorders. Founded around 2019 by MGH psychiatrists Jerry Rosenbaum, Roy Perlis, and Maurizio Fava with Brant Binder, the company applies DNA-encoded library screening (via X-Chem) and validated CNS targets. Pipeline includes PSY-05 (anxiety), PSY-06 (MDD), PSY-02 (dementia/tau aggregation), and programs in Parkinson's and chronic pain. Non-hallucinogenic, psychedelic-inspired CNS approach.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 5
- Active programmes
- 5
- Lead stage
- Preclinical
- Forecast coverage
- 5 of 5
All tracked candidates active
All tracked programmes active
Multiple active stages
5 active programmes with forecast fields
Latest sourced update
Psy Therapeutics — Pipeline
Jun 27, 2026 - company-website - Psy Therapeutics - PSY-02 (Tau Oligomerization Inhibitor)
Next known catalyst
Regulatory filing submitted
Timing not specified - PSY-05001 (Non-Opioid Analgesic) / PSY-05001 — IND-Enabling (Chronic Pain / PTSD Sleep) - Confidence: 40%
7 sources0 pipeline-linked trials0 pipeline-linked papers2 Preclinical3 Discovery
Development Programmes
5PSY-05001 (Non-Opioid Analgesic)
Preclinical
Novel non-opioid, non-addictive small molecule analgesic for subacute and chronic pain, with additional application in PTSD-related sleep disturbance. Undisclosed molecular target. Designed to provide effective pain relief without opioid misuse risk and enable transition from opioid to non-opioid treatment. US composition of matter patent allowed (protection through at least 2042); international patent applications pending. Preclinical efficacy demonstrated in neuropathic, inflammatory, and post-operative pain models.
Chronic Pain
Primary: US (FDA)
Pre-clinicalActive
Forecast
Regulatory filing submitted
IND-enabling studies in progress. Lead optimization completed. Preclinical efficacy confirmed in neuropathic, inflammatory, and post-operative pain models (Mar 2025). US composition of matter patent allowed through 2042. Company raising $10M convertible note to advance into Phase 1 FIH study and enable Series A.
Milestones
ip-milestone
CompletedActual: Jun 1, 2024
US composition of matter patent allowed for PSY-05001 / PSY-05 series with protection through at least 2042. International patent applications pending.
Why it matters: Strong IP protection secures competitive position for the lead program through 2042. Composition of matter patents are the strongest form of pharmaceutical IP.
Funding milestone
CompletedActual: Aug 15, 2024
$12.59M funding round closed. Advances PSY-05001 IND-enabling programme and broader pipeline development.
Why it matters: Largest single raise for the company. Provides runway for IND-enabling studies on lead program while maintaining multi-program pipeline development.
data-readout
CompletedActual: Mar 10, 2025
Preclinical data confirmed: PSY-05001 demonstrates efficacy in neuropathic, inflammatory, and post-operative pain models. Lead optimization completed, IND-enabling studies initiated. Company presents at Virtual Life Science Investor Forum (Mar 13, 2025).
Why it matters: Broad preclinical pain efficacy (three distinct pain models) de-risks translational potential. IND-enabling initiation marks transition from discovery to clinical development track.
Recorded Events
Mar 10, 2025: data-readout
Aug 15, 2024: Funding milestone
Jun 1, 2024: ip-milestone
Evidence Links
Psy Therapeutics — Pipeline
company-website - Psy Therapeutics - Jun 26, 2026 - Verified
PSY-05 (Anxiety / PTSD)
Preclinical
Legacy/secondary PSY-05 record for anxiety/PTSD and possibly the same chemical estate now surfaced as PSY-05001. Psy Therapeutics used the PSY-05 name in March 2025 company highlights for an oral pain/PTSD programme entering IND-enabling, while the current company pipeline lists PSY-05001 as the pain/PTSD IND-enabling asset and does not show a separate PSY-05. Treat as a mapping-cleanup item until the company clarifies nomenclature.
Anxiety Disorders
Primary: US (FDA)
Pre-clinicalActive
Forecast
programme-status-update
Public sources conflict on naming: Psy March 2025 highlights use PSY-05 for an oral pain/PTSD programme entering IND-enabling, whereas the current Psy site lists PSY-05001 for pain/PTSD and does not list a separate PSY-05. Synapse tracks PSY-05 as pending/preclinical. Keep this record visible as a mapping-cleanup and waiting-on-news item.
Evidence Links
PSY-05 — Synapse Drug Database
drug-database - Synapse / PatSnap - May 8, 2025 - Verified
Synapse/PatSnap page last updated 2025-05-08 and lists PSY-05 as pending preclinical, with anxiety disorders/PTSD in inactive indication fields.
Psy Therapeutics investor forum release with PSY-02 and PSY-05 highlights
Press release - Psy Therapeutics / GlobeNewswire - Mar 10, 2025 - Verified
Company highlights said PSY-02 tau anti-aggregation was confirmed with MJFF-financed in-vivo readouts expected in 2H25; the release also used PSY-05 for an oral pain/PTSD programme entering IND-enabling.
Synapse Psy Therapeutics organization pipeline snapshot
drug-database - Synapse / PatSnap - Jun 26, 2026 - Verified
Secondary drug-database snapshot as of 2026-06-26 lists PSY-02 as preclinical and PSY-05/PSY-06 as pending.
PSY-01 (Brain-Penetrant COMT Inhibitor)
Discovery
Novel brain-penetrant COMT (catechol-O-methyltransferase) inhibitor based on non-nitrocatechol scaffold discovered via DNA-encoded library (DEL) screen with X-Chem (200B+ molecule library). Enhances dopamine signaling. Avoids toxicity and poor brain penetration of existing nitrocatechol-based COMT inhibitors (e.g., entacapone, tolcapone). Also being explored for Parkinson's disease. NIMH SBIR Phase I grant ($458,385) awarded 2023 for depression indication. In-vivo biomarker data using touchscreen Probabilistic Reward Task (PRT) model targeted Mar 2025.
Major Depressive Disorder (MDD)
Primary: US (FDA)
DiscoveryActive
Forecast
preclinical-data
Lead optimization. NIMH SBIR Phase I funded ($458,385) — "Development of brain-penetrant COMT inhibitors for the treatment of depressive disorders." In-vivo biomarker data (PRT mouse model) targeted Mar 2025. Novel non-nitrocatechol scaffold from X-Chem DEL screen avoids liver toxicity and poor CNS penetration of existing COMT inhibitors.
Milestones
Funding milestone
CompletedActual: Jun 1, 2023
NIMH SBIR Phase I grant awarded: $458,385 for "Development of brain-penetrant COMT inhibitors for the treatment of depressive disorders." Validates novel non-nitrocatechol COMT inhibitor approach for psychiatric indications.
Why it matters: NIH peer-reviewed grant provides non-dilutive funding and scientific validation of the COMT inhibitor approach for depression — a novel mechanism distinct from SSRIs, SNRIs, and ketamine/esketamine.
Recorded Events
Jun 1, 2023: Funding milestone
Evidence Links
Psy Therapeutics — Pipeline
company-website - Psy Therapeutics - Jun 26, 2026 - Verified
PSY-02 (Tau Oligomerization Inhibitor)
Discovery
Novel oral small molecule tau oligomerization inhibitor for Alzheimer's disease, Parkinson's disease, and other tauopathies. Disease-modifying approach targeting aggregation of tau proteins. Confirmed tau anti-aggregation properties in cell-based systems. Michael J. Fox Foundation grant funded (amount undisclosed). In-vivo proof-of-concept study results expected H2 2025.
Neurocognitive Disorders
Primary: US (FDA)
DiscoveryActive
Forecast
preclinical-data
Current Psy site lists PSY-02 as a tau oligomerization inhibitor rapidly advancing through lead optimization. March 2025 company highlights said cell-based assays confirmed tau anti-aggregation and Michael J. Fox Foundation financed in-vivo proof-of-principle readouts were expected in 2H25; Synapse still lists PSY-02 as preclinical in its 2026 snapshot. No public PoC readout was found in this sweep.
Milestones
Funding milestone
CompletedActual: Jan 1, 2024
Michael J. Fox Foundation grant awarded for PSY-02 tau oligomerization inhibitor program (Parkinson's/tauopathies). Amount undisclosed. Enables in-vivo proof-of-concept studies.
Why it matters: MJFF is the world's largest private funder of Parkinson's research. Grant validates scientific premise of tau-targeting approach and provides non-dilutive capital for critical PoC studies.
Recorded Events
Jan 1, 2024: Funding milestone
Evidence Links
Psy Therapeutics — Pipeline
company-website - Psy Therapeutics - Jun 27, 2026 - Verified
Current Psy site lists PSY-02 for Parkinson disease, Alzheimer disease, and other tauopathies, rapidly advancing through lead optimization.
Psy Therapeutics investor forum release with PSY-02 and PSY-05 highlights
Press release - Psy Therapeutics / GlobeNewswire - Mar 10, 2025 - Verified
Company highlights said PSY-02 tau anti-aggregation was confirmed with MJFF-financed in-vivo readouts expected in 2H25; the release also used PSY-05 for an oral pain/PTSD programme entering IND-enabling.
Synapse Psy Therapeutics organization pipeline snapshot
drug-database - Synapse / PatSnap - Jun 26, 2026 - Verified
Secondary drug-database snapshot as of 2026-06-26 lists PSY-02 as preclinical and PSY-05/PSY-06 as pending.
PSY-06 (MDD — Potential Best-in-Class)
Discovery
Secondary sources list PSY-06 as a pending/preclinical MDD programme, but the current Psy Therapeutics site does not show a separate PSY-06 asset. Treat as a mapping-cleanup item until a company source confirms whether this remains active or has been folded into PSY-01/another MDD programme.
Major Depressive Disorder (MDD)
Primary: US (FDA)
DiscoveryActive
Forecast
programme-status-update
Psy Therapeutics current pipeline does not list a separate PSY-06 asset. Synapse tracks PSY-06 as pending/preclinical for depressive disorder in its 2026 organization snapshot and direct drug profile. Keep as secondary-source-only pending company confirmation.
Evidence Links
Psy Therapeutics — Pipeline
company-website - Psy Therapeutics - Jun 27, 2026 - Verified
PSY-06 Synapse drug database profile
drug-database - Synapse / PatSnap - May 8, 2025 - Verified
Secondary drug-database profile last updated 2025-05-08 lists PSY-06 as pending preclinical for depressive disorder.
Synapse Psy Therapeutics organization pipeline snapshot
drug-database - Synapse / PatSnap - Jun 26, 2026 - Verified
Secondary drug-database snapshot as of 2026-06-26 lists PSY-02 as preclinical and PSY-05/PSY-06 as pending.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
Alexander Shulgin Research Institute
Preclinical3 active candidates
2 shared indicationsPreclinical peer2 overlapping stagessame regulator: US FDA
Equulus Therapeutics
Preclinical2 active candidates
2 shared indicationsPreclinical peer2 overlapping stagessame regulator: US FDA
Remedi Therapeutics
Preclinical2 active candidates
3 shared indicationsPreclinical peer2 overlapping stagessame regulator: US FDA
Quick Facts
- Type
- Private Biotech
- Founded
- 2019
- Lead Stage
- Preclinical
- Website
- Visit